
GLP-1 receptor agonists (GLP-1 RAs) are now routinely encountered in preoperative assessment. Their effect on gastric emptying raises concern about pulmonary aspiration risk during anesthesia. Five major professional bodies have published perioperative guidance since 2023, reaching divergent conclusions on four clinically important questions. A systematic search of PubMed, MEDLINE, Embase, professional society websites, and grey literature was conducted for perioperative GLP-1 RA guidelines published between January 2023 and March 2026. Five documents met eligibility criteria. Each was independently appraised by two reviewers using the AGREE-REX framework, and primary studies underpinning the guidelines were reviewed for four pre-specified clinical questions. Four of five guidelines now recommend drug continuation with structured fasting modification, superseding the 2023 American Society of Anesthesiologists (ASA) cessation policy. Fasting protocols diverge substantially: SPAQI 2025 uniquely distinguishes high-calorie from low-calorie liquids. Three of five documents explicitly state that absence of gastrointestinal symptoms cannot be relied upon for risk stratification. All five guidelines endorse gastric ultrasound but none define validated decision thresholds. AGREE-REX appraisal identified the Anesthetists of Great Britain and Ireland (AAGBI)/Royal College of Anesthetists (RCoA) 2025 statement as having the broadest multidisciplinary representation and the most transparent process; Society for Perioperative Assessment and Quality Improvement (SPAQI) 2025 had the most rigorous evidence base but the most complex implementation requirements. Endocrinologist and obesity medicine representation is absent from most authoring groups, and the recommendations reflect this. International guidelines share a direction, to continue with modified fasting, but the operational details remain contested. The clinical risks of incomplete gastric emptying, hypoglycemia in insulin-dependent patients, and the absence of validated gastric ultrasound decision thresholds are not yet adequately reflected in most guidance. Prospective outcome data capturing aspiration events and glycemic complications remain urgently needed.
Neuromuscular blocking agents (NMBAs) have become a key component of anesthetic care as a means of facilitating endotracheal intubation, providing surgical relaxation of the skeletal musculature, and ensuring an immobile patient during surgical procedures. Although generally safe and effective, dosing of NMBAs and their reversal with acetylcholinesterase inhibitors (such as neostigmine) or encapsulating agents (such as sugammadex) require monitoring, including a means to quantify the degree of neuromuscular (NM) block and residual NM function. Although clinical evaluations (head lift, hip flexion, and grip strength) or respiratory parameters (tidal volume and vital capacity) have historically be used to assess return of muscle strength, these parameters have been shown to be insensitive means of detecting residual NM block and weakness. Furthermore, these subjective evaluations are not feasible during intraoperative anesthetic care and therefore cannot be used to guide initial and ongoing dosing of NMBAs, nor the adequacy of reversal. Assessing NM function using a peripheral nerve stimulator (PNS) and visual observation of the train-of-four (TOF) response was previously accepted as the standard monitor when administering NMBAs. However, subjective visual or tactile assessment is an indirect and insensitive measure of NM function, and measurement of the TOF ratio (T4/T1) is not feasible. It is generally accepted that a quantitatively determined TOF ratio ≥0.90 is the optimal method to document return of baseline NM function, avoid residual paralysis, and confirm the safe timing of tracheal extubation. The following educational review discusses the normal function of the NM junction, outlines clinical concerns of inadequate reversal of NM block, and reviews quantitative TOF monitoring with an emphasis on its use in the pediatric patient.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) enhance insulin secretion, suppress glucagon release, promote satiety, and may slow gastric emptying. Introduced in 2005 for the treatment of type 2 diabetes and obesity, these agents have prompted interest in assessing delayed gastric emptying as a potential biomarker to predict treatment response and to guide decisions regarding long-term therapy. Point-of-care gastric ultrasound (POCUS) offers a bedside method to assess gastric contents. Objectives: To compare gastric residual volume (GRV) on gastric ultrasound among patients with obesity receiving GLP-1 RAs and nonusers and those with prior weight loss surgeries. Methods: In this comparative cross-sectional pilot study, gastric POCUS was done on patients with obesity who took GLP-1 RAs and other patients with obesity with no history of taking GLP-1 RAs prior to surgery in the supine and lateral decubitus positions. Antral cross-sectional area and GRV were measured using validated mathematical models. Results: Patients receiving GLP-1 RAs demonstrated higher estimated GRV compared with nonusers. A higher proportion of GLP-1 RA users met ultrasound criteria for a full stomach. Conclusion: Among patients with obesity, GLP-1 RA therapy was associated with enlargement of the gastric antrum, increased gastric volume, and greater residual gastric contents, leading to an elevated estimated risk of aspiration. This increased risk is primarily determined by gastric ultrasound findings rather than patient characteristics, comorbidities, or duration of treatment. Gastric ultrasound may support individualized perioperative decision-making regarding aspiration precautions.
Purpose: Prolonged motor recovery associated with spinal anesthesia (SA) limits its utility in day-case surgery. We evaluated the efficacy of intravenous lipid emulsion (ILE) in accelerating recovery from sensory-motor blockade in patients undergoing day-case surgery under SA. Methods: In a double-blinded randomized study, 60 adult patients who underwent short surgical procedures under SA were randomly allocated to receive either ILE (1.5 mL/kg bolus, followed by 0.25 mL/kg/min infusion) over 30 minutes (test group) or normal saline (control group) in the immediate postoperative period. The primary objective was the time to recovery of sensory and motor blockade. The study was registered in the clinical trial registry of India CTRI/2021/11/038080 dated 11/6/2021 (www.ctri.nic.in). Results: Demographic characteristics (age, gender, American Society of Anaesthesiologists physical status grading, height, and weight) were comparable between the two groups. The recovery of sensory (200.6 ± 19.8 min versus 237.1 ± 17.9 min, P ≤ 0.001, absolute standard difference: -−1.9 (95% confidence interval [CI]: -−2.5 to -−1.3) and motor block (157.8 ± 13.1 min versus 193.6 ± 23.0 min, P ≤ 0.001, absolute standard difference: -−1.9 (95% CI: -−2.5 to -−1.3) were significantly faster in the test group compared to the control group. Conclusions: This study demonstrates that 20% ILE accelerates recovery from SA (both sensory and motor blocks), highlighting its potential utility in day-case surgery. Further trials on a larger sample size are required to validate the same. Trial Registration: CTRI/2021/11/038080 dated 11/6/2021.
Unilateral pulmonary oedema is a rare and frequently under-recognized manifestation of acute cardiogenic pulmonary oedema. Its unilateral radiographic appearance often mimics pneumonia, leading to diagnostic delay, and inappropriate initial management. Acute severe mitral regurgitation is among the most important cardiac causes of unilateral pulmonary oedema, particularly when associated with eccentric regurgitant jets directed toward the pulmonary veins.